Lyra Therapeutics, Inc. Financials
This page shows Lyra Therapeutics, Inc. (LYRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Lyra Therapeutics, Inc. has an operating margin of -6280.8%, meaning the company retains $-6281 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -4308.1% the prior year.
Lyra Therapeutics, Inc.'s revenue declined 1.5% year-over-year, from $1.6M to $1.5M. This contraction results in a growth score of 24/100.
Lyra Therapeutics, Inc. has elevated debt relative to equity (D/E of 4.72), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
With a current ratio of 3.41, Lyra Therapeutics, Inc. holds $3.41 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Lyra Therapeutics, Inc. generated -$70.0M in operating cash flow, capex of $2.3M consumed most of it, leaving -$72.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Lyra Therapeutics, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Lyra Therapeutics, Inc. generates $0.75 in operating cash flow (-$70.0M OCF vs -$93.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Lyra Therapeutics, Inc. generated $1.5M in revenue in fiscal year 2024. This represents a decrease of 1.5% from the prior year.
Lyra Therapeutics, Inc.'s EBITDA was -$95.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 43.4% from the prior year.
Lyra Therapeutics, Inc. generated -$72.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 12.4% from the prior year.
Lyra Therapeutics, Inc. reported -$93.4M in net income in fiscal year 2024. This represents a decrease of 49.1% from the prior year.
Lyra Therapeutics, Inc. earned $-1.43 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 13.5% from the prior year.
Lyra Therapeutics, Inc. held $40.6M in cash against $0 in long-term debt as of fiscal year 2024.
Lyra Therapeutics, Inc. had 1M shares outstanding in fiscal year 2024. This represents a decrease of 97.7% from the prior year.
Lyra Therapeutics, Inc.'s operating margin was -6280.8% in fiscal year 2024, reflecting core business profitability. This is down 1972.7 percentage points from the prior year.
Lyra Therapeutics, Inc.'s net profit margin was -6090.9% in fiscal year 2024, showing the share of revenue converted to profit. This is down 2067.8 percentage points from the prior year.
Lyra Therapeutics, Inc. invested $43.8M in research and development in fiscal year 2024. This represents a decrease of 8.9% from the prior year.
Lyra Therapeutics, Inc. invested $2.3M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 123.3% from the prior year.
LYRA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25K-86.3% | $183K0.0% | $183K-12.4% | $209K-65.1% | $598K+12.4% | $532K+264.4% | $146K-73.2% | $544K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $4.0M-20.8% | $5.1M+4.8% | $4.9M-23.4% | $6.4M-52.0% | $13.3M-27.3% | $18.2M+48.7% | $12.3M-0.8% | $12.4M |
| SG&A Expenses | $2.2M-36.1% | $3.5M+7.3% | $3.3M-9.7% | $3.6M-29.7% | $5.1M-11.7% | $5.8M+33.5% | $4.4M-12.9% | $5.0M |
| Operating Income | -$6.2M+29.3% | -$8.8M+0.2% | -$8.8M+22.5% | -$11.4M+76.7% | -$49.0M-108.2% | -$23.5M-42.8% | -$16.5M+2.1% | -$16.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $3K+50.0% | $2K-50.0% | $4K-33.3% | $6K-50.0% | $12K-14.3% | $14K-17.6% | $17K+6.3% | $16K |
| Net Income | -$6.0M+19.5% | -$7.4M+13.0% | -$8.5M+22.2% | -$11.0M+77.2% | -$48.1M-114.4% | -$22.5M-48.1% | -$15.2M+3.2% | -$15.7M |
| EPS (Diluted) | $-3.38+38.7% | $-5.51 | $-0.13 | $44.75 | $-36.76-10402.9% | $-0.35-84.2% | $-0.19+29.6% | $-0.27 |
LYRA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $43.7M-16.9% | $52.6M-6.6% | $56.3M-15.1% | $66.3M-29.9% | $94.6M-33.2% | $141.5M-0.8% | $142.6M+18.3% | $120.6M |
| Current Assets | $23.0M-25.9% | $31.1M-8.4% | $33.9M-21.2% | $43.0M-38.0% | $69.4M-22.4% | $89.4M-14.7% | $104.8M-0.1% | $104.9M |
| Cash & Equivalents | $22.1M-26.0% | $29.8M-6.1% | $31.7M-21.8% | $40.6M+27.2% | $31.9M+101.9% | $15.8M-29.3% | $22.4M-10.0% | $24.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $48.0M-5.7% | $51.0M-2.8% | $52.4M-4.2% | $54.8M-13.9% | $63.6M-0.7% | $64.0M+20.4% | $53.2M+46.4% | $36.3M |
| Current Liabilities | $9.5M-15.1% | $11.2M-2.7% | $11.5M-9.2% | $12.6M-34.5% | $19.3M+2.9% | $18.7M-4.5% | $19.6M+1.9% | $19.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$4.3M-366.8% | $1.6M-58.1% | $3.9M-66.6% | $11.6M-62.6% | $31.0M-60.0% | $77.5M-13.3% | $89.4M+6.2% | $84.2M |
| Retained Earnings | -$426.8M-1.4% | -$420.8M-1.8% | -$413.3M-2.1% | -$404.8M-6.0% | -$381.9M-14.4% | -$333.8M-7.2% | -$311.4M-5.1% | -$296.2M |
LYRA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.4M-11.7% | -$6.6M+25.5% | -$8.8M+22.1% | -$11.4M+43.2% | -$20.0M+11.0% | -$22.5M-17.8% | -$19.1M-35.0% | -$14.1M |
| Capital Expenditures | $0 | N/A | N/A | -$58K-129.6% | $196K-90.9% | $2.1M+173.1% | $787K+446.5% | $144K |
| Free Cash Flow | -$7.4M | N/A | N/A | -$11.4M+43.5% | -$20.2M+18.0% | -$24.6M-24.0% | -$19.8M-39.2% | -$14.3M |
| Investing Cash Flow | $0 | N/A | N/A | $28.1M-22.2% | $36.2M+360.4% | $7.9M+433.1% | -$2.4M+84.3% | -$15.0M |
| Financing Cash Flow | -$368K | N/A | N/A | -$1K+98.9% | -$89K-101.0% | $8.6M-54.3% | $18.9M+4626.3% | -$418K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
LYRA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -24948.0%-20125.0pp | -4822.9%+8.2pp | -4831.2%+627.2pp | -5458.4%+2731.3pp | -8189.6%-3767.8pp | -4421.8%+6863.8pp | -11285.6%-8192.4pp | -3093.2% |
| Net Margin | -23936.0%-19872.1pp | -4063.9%+606.6pp | -4670.5%+582.6pp | -5253.1%+2795.5pp | -8048.7%-3828.4pp | -4220.3%+6160.5pp | -10380.8%-7503.8pp | -2877.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -13.7%+0.5pp | -14.1%+1.0pp | -15.2%+1.4pp | -16.6%+34.3pp | -50.9%-35.0pp | -15.9%-5.2pp | -10.6%+2.3pp | -13.0% |
| Current Ratio | 2.43-0.4 | 2.78-0.2 | 2.96-0.5 | 3.41-0.2 | 3.60-1.2 | 4.78-0.6 | 5.35-0.1 | 5.45 |
| Debt-to-Equity | -11.10-42.5 | 31.41+17.9 | 13.54+8.8 | 4.72+2.7 | 2.05+1.2 | 0.83+0.2 | 0.59+0.2 | 0.43 |
| FCF Margin | -29444.0% | N/A | N/A | -5459.3%-2085.3pp | -3374.1%+1250.7pp | -4624.8%+8967.7pp | -13592.5%-10971.5pp | -2621.0% |
Similar Companies
Frequently Asked Questions
What is Lyra Therapeutics, Inc.'s annual revenue?
Lyra Therapeutics, Inc. (LYRA) reported $1.5M in total revenue for fiscal year 2024. This represents a -1.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lyra Therapeutics, Inc.'s revenue growing?
Lyra Therapeutics, Inc. (LYRA) revenue declined by 1.5% year-over-year, from $1.6M to $1.5M in fiscal year 2024.
Is Lyra Therapeutics, Inc. profitable?
No, Lyra Therapeutics, Inc. (LYRA) reported a net income of -$93.4M in fiscal year 2024, with a net profit margin of -6090.9%.
What is Lyra Therapeutics, Inc.'s earnings per share (EPS)?
Lyra Therapeutics, Inc. (LYRA) reported diluted earnings per share of $-1.43 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Lyra Therapeutics, Inc.'s EBITDA?
Lyra Therapeutics, Inc. (LYRA) had EBITDA of -$95.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lyra Therapeutics, Inc.'s operating margin?
Lyra Therapeutics, Inc. (LYRA) had an operating margin of -6280.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Lyra Therapeutics, Inc.'s net profit margin?
Lyra Therapeutics, Inc. (LYRA) had a net profit margin of -6090.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Lyra Therapeutics, Inc.'s free cash flow?
Lyra Therapeutics, Inc. (LYRA) generated -$72.3M in free cash flow during fiscal year 2024. This represents a -12.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lyra Therapeutics, Inc.'s operating cash flow?
Lyra Therapeutics, Inc. (LYRA) generated -$70.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Lyra Therapeutics, Inc.'s total assets?
Lyra Therapeutics, Inc. (LYRA) had $66.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Lyra Therapeutics, Inc.'s capital expenditures?
Lyra Therapeutics, Inc. (LYRA) invested $2.3M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Lyra Therapeutics, Inc. spend on research and development?
Lyra Therapeutics, Inc. (LYRA) invested $43.8M in research and development during fiscal year 2024.
How many shares does Lyra Therapeutics, Inc. have outstanding?
Lyra Therapeutics, Inc. (LYRA) had 1M shares outstanding as of fiscal year 2024.
What is Lyra Therapeutics, Inc.'s current ratio?
Lyra Therapeutics, Inc. (LYRA) had a current ratio of 3.41 as of fiscal year 2024, which is generally considered healthy.
What is Lyra Therapeutics, Inc.'s debt-to-equity ratio?
Lyra Therapeutics, Inc. (LYRA) had a debt-to-equity ratio of 4.72 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lyra Therapeutics, Inc.'s return on assets (ROA)?
Lyra Therapeutics, Inc. (LYRA) had a return on assets of -140.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Lyra Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Lyra Therapeutics, Inc. (LYRA) had $40.6M in cash against an annual operating cash burn of $70.0M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Lyra Therapeutics, Inc.'s Piotroski F-Score?
Lyra Therapeutics, Inc. (LYRA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lyra Therapeutics, Inc.'s earnings high quality?
Lyra Therapeutics, Inc. (LYRA) has an earnings quality ratio of 0.75x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Lyra Therapeutics, Inc.?
Lyra Therapeutics, Inc. (LYRA) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.